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The authors of the original article [1] have recently 
noticed that the published paper contained some errors.
In Table 2, ‘Life table showing estimates of risk of ther-
apeutic failure during 28 days follow-up in cohort of P. 
vivax monoinfection patients from southwestern India 
treated with chloroquine (25 mg/kg over 3 days) followed 
by primaquine (0.25 mg/kg daily for 14 days)’, the column 
“IR (interval risk)” should have read “CSP (cumulative 
survival probability)”. Table 2 is correctly displayed in this 
erratum.
Further, in the first paragraph of the ‘Discussion’ sec-
tion, another case report should have been mentioned 
in the final sentence, to read as follows: “Nonetheless, of 
the published literature from India, only two case reports 
dating back over two decades confirms CQ failure in P. 
vivax despite having adequate plasma concentration of 
CQ [17,18].”
A new Reference 18 [2] should have been included and 
the subsequent references renumbered to 19–26.
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Table 2 Life table showing estimates of  risk of  therapeu‑
tic failure during  28  days follow‑up in  cohort of  P. vivax 
monoinfection patients from  southwestern India treated 
with  chloroquine (25  mg/kg over  3  days) followed by  pri‑
maquine (0.25 mg/kg daily for 14 days)









0 125 0 0 1.00 0
2 125 0 0 1.00 0
3 125 0 1 0.99 0.01
7 124 3 0 0.99 0.01
14 121 0 0 0.99 0.01
21 121 0 0 0.99 0.01
28 121 0 0 0.99 0.01
The online version of the original article can be found under 
doi:10.1186/s12936-015-0824-y.
